Passage BIO (PASG) Total Liabilities (2019 - 2026)
Passage BIO (PASG) posted quarterly Total Liabilities of $24.7 million for Q1 2026, down 37.12% year-over-year from $39.3 million in Q1 2025, and down 43.23% quarter-over-quarter from $43.5 million in Q4 2025.
Passage BIO (PASG) Total Liabilities (2019 - 2026) Analysis & Trends
Passage BIO's Total Liabilities history runs 8 years deep, the most recent figure standing at $24.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 37.12% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (down 37.12% YoY), while the FY2025 annual figure was $43.5 million, up 5.77% from the prior year.
- Total Liabilities for Q1 2026 stood at $24.7 million, down from $43.5 million in the prior quarter.
- The five-year high for Total Liabilities was $51.9 million in Q1 2022, with the low at $24.7 million in Q1 2026.
- The 5-year median for Total Liabilities is $42.2 million (2022), against an average of $41.3 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 119.34% in 2022, then plunged 37.12% in 2026.
- Passage BIO's Total Liabilities stood at $42.2 million in 2022, then declined by 6.92% to $39.3 million in 2023, then climbed by 4.81% to $41.2 million in 2024, then grew by 5.77% to $43.5 million in 2025, then tumbled by 43.23% to $24.7 million in 2026.
- Business Quant data shows PASG's Total Liabilities at $24.7 million in Q1 2026, $43.5 million in Q4 2025, and $43.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 10.03 Bn |
| 10 | Passage BIO | 14.18 Mn | 14.18 Mn | - | 20.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.72 Mn |
| Mar 31, 2026 | 24.71 Mn |
| Dec 31, 2025 | 43.53 Mn |
| Sep 30, 2025 | 43.04 Mn |
| Jun 30, 2025 | 40.94 Mn |
| Mar 31, 2025 | 39.30 Mn |
| Dec 31, 2024 | 41.15 Mn |
| Sep 30, 2024 | 39.04 Mn |
| Jun 30, 2024 | 34.84 Mn |
| Mar 31, 2024 | 35.65 Mn |
| Dec 31, 2023 | 39.26 Mn |
| Sep 30, 2023 | 42.98 Mn |
| Jun 30, 2023 | 43.28 Mn |
| Mar 31, 2023 | 42.89 Mn |
| Dec 31, 2022 | 42.18 Mn |
| Sep 30, 2022 | 45.66 Mn |
| Jun 30, 2022 | 51.37 Mn |
| Mar 31, 2022 | 51.91 Mn |
| Dec 31, 2021 | 36.42 Mn |
| Sep 30, 2021 | 28.71 Mn |